Linitis Plastica: Definition, Diagnosis, and Management
What is Linitis Plastica?
Linitis plastica is a rare, aggressive form of gastric adenocarcinoma characterized by diffuse infiltrative thickening of the gastric wall (primarily submucosal and muscular layers) with a scirrhous stroma, resulting in a rigid, non-distensible stomach, often with minimal or absent mucosal abnormalities 1. This creates a diagnostic paradox where imaging suggests advanced malignancy while superficial endoscopic biopsies remain nondiagnostic 2.
The condition most commonly presents as Borrmann type IV gastric cancer with signet ring cell carcinoma (SRCC) histology, though it should not be confused with these classifications—linitis plastica is defined by its unique infiltrative pattern rather than cell type alone 1.
Clinical Presentation
Key Features to Recognize:
- Demographics: Predominantly affects females (51.9%), white patients (78.5%), and presents at advanced stage (69% stage IV at diagnosis) 3
- Symptoms: Postprandial vomiting, epigastric pain, dysphagia, early satiety, weight loss, and iron deficiency anemia 4, 5
- Physical examination: Rectal examination may reveal a rigid, concentric stricture if rectal involvement 6
- Biological behavior: Characterized by perineural invasion, nodal metastasis, and high propensity for peritoneal dissemination 7
Critical Diagnostic Pitfall:
The preserved or minimally abnormal mucosa means superficial endoscopic biopsies are frequently nondiagnostic 2, 6. When cross-sectional imaging shows the infiltrative pattern but biopsies are negative, EUS-guided deep tissue sampling should be recommended 2.
Diagnostic Workup
Imaging:
- CT/MRI findings: Diffuse circumferential wall thickening with reduced distensibility, primarily affecting submucosa and muscularis propria 2, 6
- 18F-FDG PET/CT: Useful for detecting extent of disease and guiding biopsy sites, particularly for identifying lymph node and peritoneal metastases 5
- Endoscopic appearance: Circumferential luminal narrowing with intact or minimally abnormal mucosa 6
Tissue Diagnosis:
- Multiple deep biopsies (5-8) required from ulcerated or suspicious areas 4
- EUS-guided sampling when superficial biopsies are nondiagnostic despite imaging suspicion 2
- Histopathology: Look for signet ring cells or poorly cohesive cells infiltrating submucosa with scirrhous stroma 1
Staging Requirements:
Diagnostic laparoscopy is mandatory in all cases due to the extremely high incidence of peritoneal involvement, even when not visible on cross-sectional imaging 1. This is critical as 69% present with stage IV disease 3.
Important Differential:
Metastatic invasive lobular carcinoma (ILC) of the breast is the most important mimic and may present as delayed gastric involvement years after initial breast cancer diagnosis 2. Both share loss of E-cadherin function (CDH1 mutation), explaining their convergent biology 8, 2. Always obtain breast cancer history and consider immunohistochemistry to distinguish primary gastric SRCC from metastatic ILC.
Treatment Approach
Surgical Management:
Curative-intent surgery should be performed when feasible and should not be denied based solely on the linitis plastica diagnosis 9. The data clearly shows:
- Median survival with resection: 16.7 months vs. 3.6 months without surgery (p<0.001) 9
- No significant survival difference between LP and non-LP diffuse gastric cancer after resection (16.7 vs. 23.9 months, p=0.331) 9
- Multimodal therapy (surgery + chemotherapy ± radiation) provides best outcomes with mean survival of 28.4 months 3
Total gastrectomy with D1 lymphadenectomy is recommended (extended D2 not required for prophylactic cases, though therapeutic resections follow standard gastric cancer principles) 8. Confirm esophageal squamous mucosa proximally and duodenal mucosa distally 8.
Systemic Therapy:
Follow standard gastric cancer treatment algorithms 4:
First-line:
- Platinum (oxaliplatin preferred) + fluoropyrimidine chemotherapy 4
- Add nivolumab if PD-L1 CPS ≥5 4
- Add trastuzumab if HER2-positive 4
Second-line:
Third-line:
- Trifluridine-tipiracil 4
Neoadjuvant Approach:
Recent trends show increasing use of neoadjuvant chemotherapy (chemotherapy use increased from 54.8% to 63.9% over time) 3. While no LP-specific data exists, multimodal therapy including neoadjuvant treatment appears beneficial based on improved survival with combined modality treatment 3.
Palliative Considerations:
Gastrectomy is NOT recommended in metastatic disease unless required for symptom palliation (bleeding, obstruction) 4. Early palliative care referral and nutritional support are essential 4.
Prognosis
The prognosis remains poor with:
- Overall median survival: 16.9 months 3
- 1-year survival: 33% 3
- 5-year survival: 5% 3
- Reported 4-29% survival even after "curative resection" 7
Adverse prognostic factors on multivariate analysis: Stage IV disease, no surgical resection, and no chemotherapy (all p<0.001) 3.
Key Management Principles
The absence of a linitis plastica diagnosis should not alter treatment from standard diffuse gastric cancer protocols—these patients should receive the same aggressive multimodal approach as other diffuse gastric cancers 9. The unique biology (perineural invasion, peritoneal spread) mandates thorough staging with diagnostic laparoscopy 1, but when resectable disease is confirmed, surgery combined with systemic therapy offers the only chance for meaningful survival benefit 3, 9.